• Sales
• Earnings structure
• Reconciliation to adjusted earnings
• Development of other major items in the statement of income
• Value added

Sales

In 2009, we increased Group sales by 13 % in constant currency and by 15 % at actual rates to € 14,164 million (2008: € 12,336 million).

The chart shows the various influences on Fresenius’ Group sales. Strong organic growth reached 8 %, while acquisitions contributed 5 %. Currency translation had a positive effect of 2 %. More information can be found here.

While there were no significant consequences from changes in product mix, price effects in dialysis care contributed positively. In the foreseeable future no significant changes are expected in these two factors.

Sales growth by region was as follows:

The largest regions in the Group are Europe and North America, contributing 42 % and 43 % of total sales, followed by Asia-Pacific with 8 %, and Latin America and Africa with 5 % and 2 %, respectively. Germany contributed 22 % to Group sales.

In Europe, sales were up 11 % in constant currency, with organic growth of 7 %. In North America, sales rose 16 % in constant currency. This was mainly due to the full-year consolidation of APP Pharmaceuticals. Excellent organic growth was again achieved in Asia-Pacific with 9 % and in Latin America with 12 %.

Sales growth in the business segments was as follows:

• Fresenius Medical Care achieved a sales increase of 12 % to € 8,064 million in 2009 (2008: € 7,213 million) and excellent organic growth of 8 %. Acquisitions had an effect of 1 %. Currency translation had a positive effect of 3 %. Fresenius Medical Care achieved very good increases in constant currency both in dialysis care (10 %) and in dialysis products (6 %). The growth in dialysis care was mainly due to organic growth in treatments and higher average revenues per treatment.
• Fresenius Kabi increased sales by 24 % to € 3,086 million (2008: € 2,495 million). The company achieved excellent organic growth of 8 %. Net acquisitions had an effect of 18 %. This included the acquisition of APP Pharmaceuticals and Fresenius Kabi Oncology (formerly Dabur Pharma). Currency translation had an effect of -2 % on sales. This was mainly attributable to the weaker currencies in the United Kingdom, Poland, and Mexico against the euro, while the firmer Chinese yuan, had an especially positive effect.
• Fresenius Helios increased sales by 14 % to € 2,416 million (2008: € 2,123 million) and achieved excellent organic growth of 7 %. This was mainly due to an increase in admissions compared to 2008. Net acquisitions contributed 7 %. This was attributable to the acquisition of a total of five hospitals in Saxony-Anhalt and Lower Saxony.
• Fresenius Vamed achieved excellent sales growth of 18 % to € 618 million (2008: € 524 million). Organic growth was 15 %. The clinics in the Czech Republic taken over from Fresenius Helios contributed 3 %. Sales in the project business increased by 25 % to € 420 million (2008: € 336 million). Sales in the services business rose by 5 % to € 198 million (2008: € 188 million).

Order intake and order backlog in Fresenius Vamed’s project business achieved an all-time high: order intake rose by 27 % to € 539 million (2008: € 425 million). Fresenius Vamed increased its order backlog by 19 % to € 679 million (December 31, 2008: € 571 million). This assures a stable level of capacity utilization for our business in the current year. Fresenius Vamed is the only business segment within the Fresenius Group whose business is significantly determined by order intake and order backlog. As the overview for the past five years shows, thanks to the continued strong demand for health care and hospital infrastructure we have been able to sustain the trend in order intake and order backlog despite the difficult macroeconomic development in 2008 and 2009.